Circulating hormones and breast cancer risk in premenopausal women: A randomized trial of low-dose tamoxifen and fenretinide

Breast Cancer Research and Treatment

Volumn 142, Issue 3, 2013, Pages 569-578

  Johansson, Harriet ^a   Bonanni, Bernardo ^a   Gandini, Sara ^a   Guerrieri Gonzaga, Aliana ^a   Cazzaniga, Massimiliano ^a   Serrano, Davide ^a   Macis, Debora ^a   Puccio, Antonella ^a   Sandri, Maria Teresa ^a   Gulisano, Marcella ^b   Formelli, Franca ^c   Decensi, Andrea ^d  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d GALLIERA HOSPITAL   (Italy)

Author keywords

Biomarkers; Breast density; Brest cancer; Chemoprevention; Fenretinide; Retinol; Sex hormones; SHBG; Tamoxifen

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; FENRETINIDE; FOLLITROPIN; LUTEINIZING HORMONE; PLACEBO; PRASTERONE SULFATE; PROGESTERONE; PROLACTIN; RETINOL; SEX HORMONE; SEX HORMONE BINDING PROTEIN; TAMOXIFEN; TESTOSTERONE;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MAMMOGRAPHIC DENSITY; MAMMOGRAPHY; PHASE 2 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL;

ADULT; BREAST NEOPLASMS; FEMALE; FENRETINIDE; FOLLOW-UP STUDIES; GONADAL STEROID HORMONES; HORMONES; HUMANS; INCIDENCE; MAMMARY GLANDS, HUMAN; MIDDLE AGED; PREMENOPAUSE; RISK; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; TAMOXIFEN; VITAMIN A;

EID: 84890311216     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2768-7     Document Type: Article

References (50)

1. Lazzeroni M, Serrano D, Dunn BK, Heckman-Stoddard BM, Lee O, Khan S, Decensi A (2012) Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug. Breast Cancer Res 14:214
2. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A (2006) Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer 13:51-68
3. Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, Di Mauro MG, Costa A, Marubini E, Sporn MB, De Palo G (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17:1065-1071
4. Boyd NF, Melnichouk O, Martin LJ, Hislop G, Chiarelli AM, Yaffe MJ, Minkin S (2011) Mammographic density, response to hormones, and breast cancer risk. J Clin Oncol 29:2985-2992
5. Aiello EJ, Tworoger SS, Yasui Y, Stanczyk FZ, Potter J, Ulrich CM, Irwin M, McTiernan A (2005) Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women. Cancer Epidemiol Biomarkers Prev 14:1411-1417
6. Boyd NF, Stone J, Martin LJ, Jong R, Fishell E, Yaffe M, Hammond G, Minkin S (2002) The association of breast mitogens with mammographic densities. Br J Cancer 87:876-882
7. Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Berube S, Morin C, Brisson J (2005) Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14:1065-1073
8. Greendale GA, Palla SL, Ursin G, Laughlin GA, Crandall C, Pike MC, Reboussin BA (2005) The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol 162:826-834
9. Maskarinec G, Williams AE, Kaaks R (2003) A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 107:991-996
10. Noh JJ, Maskarinec G, Pagano I, Cheung LW, Stanczyk FZ (2006) Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women. Breast 15:20-28
11. Tamimi RM, Hankinson SE, Colditz GA, Byrne C (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomarkers Prev 14:2641-2647
12. Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12:21-29
13. Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, Rollison DE, Dorgan JF, Brinton LA, Overvad K, Kaaks R, Trichopoulou A, Clavel-Chapelon F, Panico S, Duell EJ, Peeters PH, Rinaldi S, Fentiman IS, Dowsett M, Manjer J, Lenner P, Hallmans G, Baglietto L, English DR, Giles GG, Hopper JL, Severi G, Morris HA, Hankinson SE, Tworoger SS, Koenig K, Zeleniuch-Jacquotte A, Arslan AA, Toniolo P, Shore RE, Krogh V, Micheli A, Berrino F, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Lui LY, Cummings SR, Gunter MJ, Rohan TE, Strickler HD (2011) Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 105:709-722
14. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591
15. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HEJ, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR (2003) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95:1218-1226
16. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98:1406-1415
17. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quiros JR, Roddam A, Thiebaut A, Tjonneland A, Chirlaque MD, Trichopoulou A, Trichopoulos D, Tumino R, Vineis P, Norat T, Ferrari P, Slimani N, Riboli E (2005) Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97:755-765
18. Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, Sieri S, Pala V, Berrino F (2004) Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 112:312-318
19. Dorgan JF, Stanczyk FZ, Kahle LL, Brinton LA (2010) Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Res 12:R98
20. Formelli F, Meneghini E, Cavadini E, Camerini T, Di Mauro MG, De PG, Veronesi U, Berrino F, Micheli A (2009) Plasma retinol and prognosis of postmenopausal breast cancer patients. Cancer Epidemiol Biomarkers Prev 18:42-48
21. Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Galimberti V, Cassano E, Moroni SM, Formelli F, Lien EA, Pelosi G, Johnson KA, Bonanni B (2009) Randomized double-blind 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 27:3749-3756
22. Guerrieri-Gonzaga A, Robertson C, Bonanni B, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Intra M, Latronico A, Franchi D, Pelosi G, Johnson K, Decensi A (2006) Preliminary results on safety and activity of a randomized, double-blind, 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol 24:129-135
23. Cohen I, Figer A, Tepper R, Shapira J, Altaras MM, Yigael D, Beyth Y (1999) Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. Gynecol Oncol 72:202-207
24. Groom GV, Griffiths K (1976) Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70:421-428
25. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC (1991) Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83:1488-1491
26. Sherman BM, Chapler FK, Crickard K, Wycoff D (1979) Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 64:398-404
27. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, Veronesi P, Torrisi R, Cazzaniga M, Mora S, Sandri MT, Pelosi G, Luini A, Goldhirsch A, Lien EA, Veronesi U (2003) A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95:779-79028
28. Johansson H, Cazzaniga M, Bonanni B, Mora S, Mariette F, Pelosi G, Lien E, Robertson C, Decensi A (2006) Effects of low dose tamoxifen on circulating levels of hormones, C-telopeptide and HER2 extracellular domain in women with primary breast cancer. AACR Annual Meeting, Washington
29. Ellmen J, Hakulinen P, Partanen A, Hayes DF (2003) Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res Treat 82:103-111
30. Lonning PE, Johannessen DC, Lien EA, Ekse D, Fotsis T, Adlercreutz H (1995) Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 52:491-496
31. Bonanni B, Serrano D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Macis D, Cazzaniga M, Luini A, Cassano E, Oldani S, Lien EA, Pelosi G, Decensi A (2009) Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia. Clin Cancer Res 15:7053-7060
32. Sakai F, Cheix F, Clavel M, Colon J, Mayer M, Pommatau E, Saez S (1978) Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrinol 76:219-226
33. Bruning PF, Bonfrer JM, Hart AA, de Jong-Bakker M, Linders D, van LJ, Nooyen WJ (1988) Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 58:497-499
34. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD (1989) A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60:126-131
35. Bernardes JR Jr, Nonogaki S, Seixas MT, de Rodrigues LG, Baracat EC, Gebrim LH (1999) Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue. Int J Gynaecol Obstet 67:33-38
36. Barkhem T, ndersson-Ross C, Hoglund M, Nilsson S (1997) Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes. J Steroid Biochem Mol Biol 62:53-64
37. Browne-Martin K, Longcope C (2001) Regulation of sex hormone-binding globulin secretion in human hepatoma G2 cells. Steroids 66:605-607
38. Fortunati N, Catalano MG, Boccuzzi G, Frairia R (2010) Sex Hormone-Binding Globulin (SHBG), estradiol and breast cancer. Mol Cell Endocrinol 316:86-92
39. Formelli F, Carsana R, Costa A, Buranelli F, Campa T, Dossena G, Magni A, Pizzichetta M (1989) Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res 49:6149-6152
40. Ciolino HP, Wang TT, Sathyamoorthy N (2000) Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide. Br J Cancer 83:333-337
41. Ciolino HP, Dai Z, Nair V (2011) Retinol inhibits aromatase activity and expression in vitro. J Nutr Biochem 22:522-526
42. Johansson H, Gandini S, Bonanni B, Mariette F, Guerrieri-Gonzaga A, Serrano D, Cassano E, Ramazzotto F, Baglietto L, Sandri MT, Decensi A (2008) Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Breast Cancer Res Treat 108:57-67
43. Walker K, Fletcher O, Johnson N, Coupland B, McCormack VA, Folkerd E, Gibson L, Hillier SG, Holly JM, Moss S, Dowsett M, Peto J, dos SSI (2009) Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res 69:6490-6499
44. Warren R, Skinner J, Sala E, Denton E, Dowsett M, Folkerd E, Healey CS, Dunning A, Doody D, Ponder B, Luben RN, Day NE, Easton D (2006) Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:1502-1508
45. Aiello EJ, Tworoger SS, Yasui Y, Stanczyk FZ, Potter J, Ulrich CM, Irwin M, McTiernan A (2005) Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women. Cancer Epidemiol Biomarkers Prev 14:1411-1417
46. Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, McLean C, Morris HA, Tilley WD, Giles GG (2010) Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers Prev 19:492-502
47. Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606-616
48. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiebaut A, Gonzalez CA, Quiros JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12:1071-1082
49. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quiros JR, Roddam A, Thiebaut A, Tjonneland A, Chirlaque MD, Trichopoulou A, Trichopoulos D, Tumino R, Vineis P, Norat T, Ferrari P, Slimani N, Riboli E (2005) Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97:755-765
50. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rates: a practical and powerful approach to multiple testing. J R Stat Soc B 35:289-300